Schizophrenia Drugs Market Size, Share & Industry Analysis, By Therapeutic Class (Second Generation, Third Generation, Others), By Treatment (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others) and Regional Forecast, 2020-2029 (Includes COVID-19 Business Impact)

                                          
We have updated Schizophrenia Drugs Market with respect to COVID-19 Business Impact.

Inquire before buying

This report focuses on the Schizophrenia Drugs market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Schizophrenia Drugs market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.


Global Schizophrenia Drugs Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.


Global Schizophrenia Drugs Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.


Global Schizophrenia Drugs Market: Competitive Landscape


This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

Market players like H. Lundbeck A/S, Otsuka Pharmaceutical Co., Ltd., Inc., and Janssen Pharmaceuticals, Inc. will execute strategies to ensure the strengthening of market position with respect to providing schizophrenia drugs with improved efficacy and safety features H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. is actively developing schizophrenia treatment drugs in order to increase and strengthen their market share. A greater focus is being directed towards the development of long acting injectable and newer generations of schizophrenia drugs.

Alkermes has been actively working on developing schizophrenia drugs such as the ALKS 3831. ALKS 3831 is a combination of olanzapine and samidorphan. ALKS 3831 was able to successfully mitigate the weight gain experienced by the patients using schizophrenia drugs and was able to post a successful Phase 3 clinical trial result.

List Of Key Companies Profiled

  
H. Lundbeck A/S

  
Otsuka Pharmaceutical Co., Ltd.
  
Janssen Pharmaceuticals, Inc.
  
Eli Lilly and Company
  
AstraZeneca
  
ALLERGAN
  
Vanda Pharmaceuticals Inc.
  
Sumitomo Dainippon Pharma Co., Ltd.
  
Alkermes plc
  
Bristol-Myers Squibb Company
  
Other Prominent Players

REPORT COVERAGE
"A growing trend observed in the increasing adoption of advanced and more efficient schizophrenia drugs across the developed and developing markets."
The report provides qualitative and quantitative insights on the global schizophrenia therapeutics market and detailed analysis of global market size & growth rate for all possible segments in the market. The global market is segmented By therapeutic class, treatment, and geography. Based on the therapeutic class, the global market is classified into second generation, third generation and others. Based on the treatment, the market is segmented into the oral and injectable. By distribution channel, the global market is classified as hospital pharmacies, retail pharmacies, online pharmacies, and others. Geographically, the global market has been analyzed across five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. These regions are further categorized into countries.

competitive landscape. Various key insights presented in the report are the overview of prevalence of schizophrenia by key regions, pipeline analysis, key industry developments, new product launches, analysis of the cost and burden of schizophrenia, analysis of first generation antipsychotics versus second & third generation antipsychotics, and overview of R&D initiatives.

Report Scope & Segmentation

 Segmentation

By Therapeutic Class

  
Second Generation
  
Third Generation
  
Others

By Treatment

  
Oral
  
Injectable

By Distribution Channel

  
Hospital Pharmacies
  
Retail Pharmacies
  
Online Pharmacies
  
Others

By Geography

  
North America (U.S. and Canada)
  
Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  
Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  
Latin America (Brazil, Mexico, and Rest of Latin America)
  
Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

INDUSTRY DEVELOPMENT:

July 2018: The new antipsychotic drug called Perseris, an extended-release injectable form of risperidone from Indivior PLC won the FDA approval for the treatment of schizophrenia.

April 2019: Otsuka Pharmaceutical Co., Ltd. announced the launch of REXULTI tablets for the treatment of schizophrenia in Japan.